References

Preoperative assessment guidelines
NHS Forth Valley
  1. McIlmoyle K and Tran H. Perioperative Management of oral anticoagulation. BJA Education 2018;18(9): 259-264.
  2. Kreutz, R et al .Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: A randomized crossover study. Journal of Thrombosis and Haemostasis. 2017. 15. 10.1111/jth.13801.
  3. Parasrampuria, D, Truitt, K. Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. Clin Pharmacokinet (2016). 55, 641–655 https://doi.org/10.1007/s40262-015-0342-
  4. T and West S. Regional Anaesthesia in patients at risk of bleeding. BJA Education 2021; 21(3): 84-94.
  5. Griffiths, R., Babu, S., Dixon, P., Freeman, N., Hurford, D., Kelleher, E., Moppett, I., Ray, D., Sahota, O., Shields, M. and White, S. (2021), Guideline for the management of hip fractures 2020. Anaesthesia, 76: 225-237. https://doi.org/10.1111/anae.15291
  6. andexanet alfa (Ondexxya) (scottishmedicines.org.uk)
  7. Douketis JD et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Intern Med. 2019 Nov 1;179(11):1469-1478. doi: 10.1001/jamainternmed.2019.2431. PMID: 31380891; PMCID: PMC6686768.
  8. idarucizumab (Praxbind) (scottishmedicines.org.uk)